Wolfram Klapper
Professor of Pathology
University Hospital Schleswig-Holstein · Kiel, Germany
Reference pathologist for the European MCL Network. Expert in MCL diagnosis, Ki-67 proliferation index, and morphologic classification.
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Lancet (London, England) · May 16, 2026
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.
Leukemia · Dec 1, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Haematologica · Oct 30, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
Leukemia · Dec 1, 2024
SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features.
Blood · Jul 11, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia · Jun 1, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet (London, England) · May 25, 2024